摘要
目的:探讨不同剂量阿托伐他汀对颈动脉狭窄(CAS)支架植入术后再狭窄的预防作用。方法:将我院收治的86例行支架植入术的CAS患者按随机数字表法分为大剂量组(阿托伐他汀20 mg/d)和小剂量组(阿托伐他汀10 mg/d),各43例,均治疗12个月,比较两组治疗效果。结果:治疗后大剂量组CAS改善情况优于对照组,差异有统计学意义(P <0.05);大剂量组脑卒中复发率低于小剂量组,差异有统计学意义(P <0.05);治疗后大剂量组改良的RANKIN量表(mRS)评分小于小剂量组,差异有统计学意义(P <0.05);治疗后大剂量组血白细胞介素(IL)-6、肿瘤坏死因子(TNF)-α、丙二醛(MDA)及氧化修饰低密度脂蛋白(ox-LDL)水平低于小剂量组,差异有统计学意义(P <0.05)。结论:高剂量阿托伐他汀可有效预防CAS患者支架植入术后再狭窄的发生,促进神经功能恢复,减少炎症反应。
Objective:To investigate the preventive effect of different doses of atorvastatin on restenosis after carotid artery stenosis(CAS)stent implantation.Methods:86 CAS patients who underwent stent implantation in our hospital were randomly divided into a high-dose group(atorvastatin 20 mg/d)and a low-dose group(atorvastatin 10 mg)./d),43 cases each.All patients were treated for 12 months.The therapeutic effect were compared between the two groups.Results:After treatment,the improvement of CAS in the high-dose group was better than that in the low-dose group,and the difference was statistically significant(P<0.05).The recurrence rate of stroke in the highdose group was lower than that in the low-dose group,and the difference was statistically significant(P<0.05).After treatment,the scores of modified RANKIN scale(mRS)in the high-dose group were lower than those in the low-dose group,and the difference was statistically significant(P<0.05).After treatment,the levels of blood interleukin(IL)-6,tumor necrosis factor(TNF)-α,malondialdehyde(MDA)and oxidized low-density lipoprotein(ox-LDL)in the highdose group were lower than those in the low-dose group,and the differences were statistically significant(P<0.05).Conclusion:High-dose atorvastatin can effectively prevent the occurrence of restenosis after stent implantation in patients with CAS,promote the recovery of nerve functions and reduce inflammatory response.
作者
朱志超
张艳华
朱艳玲
Zhu Zhi-chao;Zhang Yan-hua;Zhu Yan-ling(Department of Pharmacy,General Hospital of Hebi Coal Industry Group(Limited),Anyang,Henan 458000,China;Department of Neurology,General Hospital of Hebi Coal Industry Group(Limited),Anyang,Henan 458000,China)
出处
《中国合理用药探索》
CAS
2019年第2期117-120,共4页
Chinese Journal of Rational Drug Use
